The authors have carried out the laboratory and clinical studies of fosfomycin-Na. The results were as follows. The sensitivity was measured by the plate dilution method with 31 strains of Staph. aureus and 32 strains of Pseudomonas aeruginosa isolated from patients. The growth of all strains of Staph. aureus was inhibited in concentration of less than 25μg/ml. The growth of 31 of 32 strains of Pseudomonas aeruginosa was inhibited in concentration of less than 50μg/ml. And the peak of distribution of sensitivity of Staph. aureus and Pseudomonas aeruginosa to fosfomycin was at 6.25 μg/ml and 25μg/ml, respectively.
Fosfomycin-Na was given a single intravenous dose of 500 mg to 2 children.
The maximum blood level was reached at 15 minutes and 30 minutes after administration, 92μg/ml and 36.0μg/ml, respectively.
The excretion rate of fosfomycin in the urine after a single intravenous dosing was 35.5-41.4% up to 6 hours of period.
Fosfomycin-Na was effective in 3 of 4 cases of serious bacterial infections (Pseudomonas sepsis and staphylococcal pyothorax).
Phlebitis was observed in one patient.
